OncoSec Medical To Present at Bioelectrochemistry Gordon Research Conference on July 8 and July 10
July 02 2014 - 6:02AM
Business Wire
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its
ImmunoPulse DNA-based intratumoral cancer immunotherapy, announces
that Robert Pierce, M.D., Chief Medical Officer, and Richard
Heller, Ph.D., Scientific Advisory Board member, will present at
the Bioelectrochemistry Gordon Research Conference being held July
6-11, 2014 at the University of New England in Biddeford, ME.
Dr. Pierce will present a discussion titled “GET-IT!
Intratumoral Electro-Gene Transfer of Immunomodulatory DNA in
Oncology" on Tuesday, July 8 at 12:00 pm ET. The discussion will be
a part of the track titled “Pore-Inducing Methods for Gene
Transfer.”
Dr. Heller will present a discussion titled “New Developments in
Gene Electro Transfer and Potential Clinical Translation” on
Thursday, July 10 at 8:30 pm ET. The discussion will be a part of
the track titled “Electroporation-Mediated Gene Delivery.”
About the Bioelectrochemistry Gordon Research
Conference
The 2014 Gordon Research Conference will bring together leading
researchers and clinicians to focus on molecular mechanisms related
to the many aspects of bioelectrochemistry, and to discuss new and
innovative studies that will expand our knowledge and appreciation
of the field. The conference is unique in its design to bring
together key field leaders to consider how these techniques can be
developed further to yield novel clinical applications. While the
meeting covers many divergent areas, great emphasis will be placed
on stressing the connections between the planned sessions so that
all participants are engaged to create a unified meeting. Attendees
are encouraged to present posters that stimulate additional
discussions, and the conference provides an excellent opportunity
for junior researchers to present their work to leaders in the
field within a uniquely constructive atmosphere. For more
information, please visit the conference web site via the following
link: http://www.grc.org
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing
its ImmunoPulse immunotherapy to treat solid tumors. OncoSec
Medical's core technology leverages a proprietary electroporation
platform to enhance the local delivery and uptake of DNA
IL-12 and other DNA-based immune-modulating agents. Clinical
studies of ImmunoPulse have demonstrated an acceptable safety
profile and preliminary evidence of anti-tumor activity in the
treatment of various skin cancers, as well as the potential to
initiate a systemic immune response without the systemic toxicities
associated with other treatments. OncoSec's clinical programs
currently include three Phase 2 trials targeting metastatic
melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma,
conducted in collaboration with several prominent academic medical
centers. As the company continues to evaluate ImmunoPulse in these
indications, it is also investigating additional indications and
combination therapeutic approaches. For more information, please
visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
OncoSec Medical Inc.Veronica Vallejo,
CFO855-662-6732investors@oncosec.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024